Loading page
Loading page
Loading substance route
Produces a strong metallic taste and pronounced mouth and tongue numbness lasting up to an hour after absorption. Must be held sublingually for 15-25 minutes. Not orally active. Insufflation is contraindicated due to documented deaths and hospitalizations in closely related NBOMe compounds.
These combinations are considered extremely harmful and should always be avoided. Reactions to these drugs taken in combination are highly unpredictable and have a potential to cause death.
There is considerable risk of physical harm when taking these combinations, they should be avoided where possible.
These combinations are not usually physically harmful, but may produce undesirable effects, such as physical discomfort or overstimulation. Extreme use may cause physical health issues. Synergistic effects may be unpredictable. Care should be taken when choosing to use this combination.
25B-NBOH is not habit-forming and the desire to use it can actually decrease with use. It is described as most often self-regulating.
The LD50 has not been determined. While no deaths have been specifically reported for 25B-NBOH, it is assumed to share a similar toxicity profile with 25B-NBOMe, which has been linked to multiple deaths. The compound's extreme potency and highly sensitive dose-response curve suggest it may be potentially fatal at heavy doses. Insufflation is particularly dangerous due to dosing difficulties and has been associated with deaths and hospitalizations with closely related 25x-NBOMe compounds.
Acute cardiovascular effects including increased heart rate, elevated blood pressure, abnormal heartbeat, and vasoconstriction occur during intoxication; the long-term clinical significance in occasional users is not characterized due to limited research.
Anxiety and paranoia appear to occur more readily than with many other psychedelics, potentially due to the compound's prominent stimulating properties. High doses can lead to states of confusion, amnesia, and general sensory overload. Unpredictable dose-response effects may contribute to psychological risk.
Seizures are listed among reported physical effects, though frequency and precipitating conditions are not well characterized due to limited human data.
25B-NBOH was first synthesized and documented in 2011 by Martin Hansen at the University of Copenhagen. The compound is a structural derivative of the phenethylamine psychedelic 2C-B, belonging to the broader family of N-benzyl phenethylamines and sharing close structural relationships with the…
Added to the controlled substances list under Portaria SVS/MS nº 344 on December 10, 2018. Possession, distribution, and use are prohibited under Brazilian law.
Listed under Schedule I of the Narcotic Drugs Punishments Act, a classification for substances without recognized medical use. The scheduling was published by the Medical Products Agency in regulation HSLF-FS 2015:35.
Classified as a Class A controlled substance under the Misuse of Drugs Act 1971 through the N-benzylphenethylamine catch-all provision. Class A substances carry the most severe penalties under UK drug law.
Regulated under the Neue-psychoaktive-Stoffe-Gesetz (New Psychoactive Substances Act) since November 26, 2016. Production and import with intent to distribute, administration to others, and commercial trading are criminally punishable. Personal possession is prohibited but not subject to criminal penalty.
Regulated as a defined derivative of N-benzylphenethylamine under Verzeichnis E, point 131 of Swiss controlled substances legislation. An exemption exists permitting use for scientific or industrial purposes.
Not explicitly scheduled under the Controlled Substances Act. However, possession or distribution intended for human consumption may be prosecuted under the Federal Analogue Act due to structural and pharmacological similarities to the Schedule I substance 25B-NBOMe.
15 sources cited